A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate

P. S. Chen, H. H. Chang, C. C. Huang, C. C. Lee, S. Y. Lee, S. L. Chen, S. Y. Huang, Y. K. Yang, R. B. Lu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This longitudinal study aimed to investigate the associations between the polymorphisms of guanine nucleotide-binding protein subunit β-3 (GNB3) C825T and metabolic disturbance in bipolar II disorder (BP-II) patients being treated with valproate (VPA). A 100 BP-II patients received a 12-week course of VPA treatment, and their body weight and metabolic indices were measured. At baseline, the GNB3 C825T polymorphisms were associated with the triglyceride level (P=0.032) in BP-II patients. During the VPA treatment course, the polymorphisms were not only associated with body mass index (BMI) and waist circumference (P-values=0.009 and 0.001, respectively), but also with total cholesterol, triglyceride, low-density lipoprotein and leptin levels (P-values=0.004, 0.002, 0.031 and 0.015, respectively). Patients with the TT genotype had a lower BMI, smaller waist circumference, and lower levels of lipids and leptin than those with the CT or CC genotypes undergoing the VPA treatment course.

Original languageEnglish
Pages (from-to)155-161
Number of pages7
JournalPharmacogenomics Journal
Volume17
Issue number2
DOIs
Publication statusPublished - Mar 1 2017
Externally publishedYes

Fingerprint

Guanine Nucleotides
Protein Subunits
Valproic Acid
Longitudinal Studies
Carrier Proteins
Bipolar Disorder
Waist Circumference
Leptin
Body Mass Index
Genotype
LDL Cholesterol
Triglycerides
Therapeutics
Body Weight
Lipids

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate. / Chen, P. S.; Chang, H. H.; Huang, C. C.; Lee, C. C.; Lee, S. Y.; Chen, S. L.; Huang, S. Y.; Yang, Y. K.; Lu, R. B.

In: Pharmacogenomics Journal, Vol. 17, No. 2, 01.03.2017, p. 155-161.

Research output: Contribution to journalArticle

Chen, P. S. ; Chang, H. H. ; Huang, C. C. ; Lee, C. C. ; Lee, S. Y. ; Chen, S. L. ; Huang, S. Y. ; Yang, Y. K. ; Lu, R. B. / A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate. In: Pharmacogenomics Journal. 2017 ; Vol. 17, No. 2. pp. 155-161.
@article{9556c6655e3d4a368a813117e409735d,
title = "A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate",
abstract = "This longitudinal study aimed to investigate the associations between the polymorphisms of guanine nucleotide-binding protein subunit β-3 (GNB3) C825T and metabolic disturbance in bipolar II disorder (BP-II) patients being treated with valproate (VPA). A 100 BP-II patients received a 12-week course of VPA treatment, and their body weight and metabolic indices were measured. At baseline, the GNB3 C825T polymorphisms were associated with the triglyceride level (P=0.032) in BP-II patients. During the VPA treatment course, the polymorphisms were not only associated with body mass index (BMI) and waist circumference (P-values=0.009 and 0.001, respectively), but also with total cholesterol, triglyceride, low-density lipoprotein and leptin levels (P-values=0.004, 0.002, 0.031 and 0.015, respectively). Patients with the TT genotype had a lower BMI, smaller waist circumference, and lower levels of lipids and leptin than those with the CT or CC genotypes undergoing the VPA treatment course.",
author = "Chen, {P. S.} and Chang, {H. H.} and Huang, {C. C.} and Lee, {C. C.} and Lee, {S. Y.} and Chen, {S. L.} and Huang, {S. Y.} and Yang, {Y. K.} and Lu, {R. B.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1038/tpj.2015.96",
language = "English",
volume = "17",
pages = "155--161",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate

AU - Chen, P. S.

AU - Chang, H. H.

AU - Huang, C. C.

AU - Lee, C. C.

AU - Lee, S. Y.

AU - Chen, S. L.

AU - Huang, S. Y.

AU - Yang, Y. K.

AU - Lu, R. B.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - This longitudinal study aimed to investigate the associations between the polymorphisms of guanine nucleotide-binding protein subunit β-3 (GNB3) C825T and metabolic disturbance in bipolar II disorder (BP-II) patients being treated with valproate (VPA). A 100 BP-II patients received a 12-week course of VPA treatment, and their body weight and metabolic indices were measured. At baseline, the GNB3 C825T polymorphisms were associated with the triglyceride level (P=0.032) in BP-II patients. During the VPA treatment course, the polymorphisms were not only associated with body mass index (BMI) and waist circumference (P-values=0.009 and 0.001, respectively), but also with total cholesterol, triglyceride, low-density lipoprotein and leptin levels (P-values=0.004, 0.002, 0.031 and 0.015, respectively). Patients with the TT genotype had a lower BMI, smaller waist circumference, and lower levels of lipids and leptin than those with the CT or CC genotypes undergoing the VPA treatment course.

AB - This longitudinal study aimed to investigate the associations between the polymorphisms of guanine nucleotide-binding protein subunit β-3 (GNB3) C825T and metabolic disturbance in bipolar II disorder (BP-II) patients being treated with valproate (VPA). A 100 BP-II patients received a 12-week course of VPA treatment, and their body weight and metabolic indices were measured. At baseline, the GNB3 C825T polymorphisms were associated with the triglyceride level (P=0.032) in BP-II patients. During the VPA treatment course, the polymorphisms were not only associated with body mass index (BMI) and waist circumference (P-values=0.009 and 0.001, respectively), but also with total cholesterol, triglyceride, low-density lipoprotein and leptin levels (P-values=0.004, 0.002, 0.031 and 0.015, respectively). Patients with the TT genotype had a lower BMI, smaller waist circumference, and lower levels of lipids and leptin than those with the CT or CC genotypes undergoing the VPA treatment course.

UR - http://www.scopus.com/inward/record.url?scp=84957825141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957825141&partnerID=8YFLogxK

U2 - 10.1038/tpj.2015.96

DO - 10.1038/tpj.2015.96

M3 - Article

C2 - 26856249

AN - SCOPUS:84957825141

VL - 17

SP - 155

EP - 161

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 2

ER -